Therapeutic Targets from the Perspective of Blood–Brain Barrier (BBB) Shuttling Who Can Truly Deliver Drugs into the Brain
The blood–brain barrier (BBB) is emerging as a critical gateway for drug delivery to the central nervous system. With agents such as Trontinemab and Pabinafusp alfa advancing into clinical validation, BBB shuttling mechanisms are reshaping the criteria for assessing target druggability.